Management of precipitated opiate withdrawal syndrome induced by nalmefene mistakenly prescribed in opiate-dependent patients: a review for clinicians

References

• Kourounis G, Richards BD, Kyprianou E, et al. Opioid substitution therapy: lowering the treatment thresholds. Drug Alcohol Depend. 2016;161:1–8.
   PubMed Web of Science ®Google Scholar
• Delorme J, Chenaf C, Kabore J-L, et al. Incidence of high dosage buprenorphine and methadone shopping behavior in a retrospective cohort of opioid-maintained patients in France. Drug Alcohol Depend. 2016;162:99–106.
   PubMed Web of Science ®Google Scholar
• Clausen T, Anchersen K, Waal H. Mortality prior to, during and after opioid maintenance treatment (OMT): a national prospective cross-registry study. Drug Alcohol Depend. 2008;94(1–3):151–157.
   PubMed Web of Science ®Google Scholar
• Dennis BB, Roshanov PS, Naji L, et al. Opioid substitution and antagonist therapy trials exclude the common addiction patient: a systematic review and analysis of eligibility criteria. Trials. 2015;16:475.
   PubMed Web of Science ®Google Scholar
• Grant BF, Saha TD, Ruan WJ, et al. Epidemiology of DSM-5 drug use disorder: results from the national epidemiologic survey on alcohol and related conditions-III. JAMA Psychiatry. 2016;73(1):39–47.
   PubMed Web of Science ®Google Scholar
• Nutt DJ. The role of the opioid system in alcohol dependence. J Psychopharmacol. 2014;28(1):8–22. .
   PubMed Web of Science ®Google Scholar
• Backmund M, Schütz CG, Meyer K, et al. Alcohol consumption in heroin users, methadone-substituted and codeine-substituted patients – frequency and correlates of use. Eur Addict Res. 2003;9(1):45–50.
   PubMed Web of Science ®Google Scholar
• Dahmke H, Kupferschmidt H, Kullak-Ublick GA, et al. Nalmefene and opioid withdrawal syndrome: analysis of the global pharmacovigilance database for adverse drug reactions. Praxis. 2015;104(21):1129–1134.
   PubMedGoogle Scholar
• Diot C, Eiden C, Roussin A, et al. Withdrawal syndrome after co-medication of opioid maintenance therapy with nalmefene: unrecognized interaction. Eur J Clin Pharmacol. 2015;71(12):1539–1540.
   PubMed Web of Science ®Google Scholar
• Donnerstag N, Schneider T, Lüthi A. et al. Severe opioid withdrawal syndrome after a single dose of nalmefene. Eur J Clin Pharmacol. 2015;71(8):1025–1026.
   PubMed Web of Science ®Google Scholar
• Pélissier F, Rougé Bugat M-E, Nubukpo P. et al. Nalmefene mistakenly prescribed to reduce alcohol consumption in patients under buprenorphine substitution therapy resulting in acute opioid withdrawal: management in an emergency setting. J Clin Psychopharmacol. 2016;36(1):100–103.
   PubMed Web of Science ®Google Scholar
• O’Brien CP. Anticraving medications for relapse prevention: a possible new class of psychoactive medications. Am J Psychiatry. 2005;162(8):1423–1431.
   PubMed Web of Science ®Google Scholar
• Di Chiara G, North RA. Neurobiology of opiate abuse. Trends Pharmacol Sci. 1992;13(5):185–193.
   PubMed Web of Science ®Google Scholar
• Koob GF. Neurobiology of addiction: toward the development of new therapies. Ann N Y Acad Sci. 2000;909(1):170–185.
   PubMed Web of Science ®Google Scholar
• Marinelli PW, Bai L, Quirion R, et al. A microdialysis profile of Met-enkephalin release in the rat nucleus accumbens following alcohol administration. Alcohol Clin Exp Res. 2005;29(10):1821–1828.
   PubMed Web of Science ®Google Scholar
• Mitchell JM, Bergren LJ, Chen KS, et al. Naltrexone aversion and treatment efficacy are greatest in humans and rats that actively consume high levels of alcohol. Neurobiol Dis. 2009;33(1):72–80.
   PubMed Web of Science ®Google Scholar
• Cunningham CL, Henderson CM, Bormann NM. Extinction of ethanol-induced conditioned place preference and conditioned place aversion: effects of naloxone. Psychopharmacology. 1998;139(1–2):62–70.
   PubMed Web of Science ®Google Scholar
• Bormann NM, Cunningham CL. The effects of naloxone on expression and acquisition of ethanol place conditioning in rats. Pharmacol Biochem Behav. 1997;58(4):975–982.
   PubMed Web of Science ®Google Scholar
• Koob GF, Le Moal M. Plasticity of reward neurocircuitry and the ‘dark side’ of drug addiction. Nat Neurosci. 2005;8(11):1442–1444.
   PubMed Web of Science ®Google Scholar
• Bart G, Schluger JH, Borg L, et al. Nalmefene induced elevation in serum prolactin in normal human volunteers: partial kappa opioid agonist activity? Neuropsychopharmacology. 2005;30(12):2254–2262.
   PubMed Web of Science ®Google Scholar
• Walker BM, Koob GF. Pharmacological evidence for a motivational role of kappa-opioid systems in ethanol dependence. Neuropsychopharmacol. 2008;33(3):643–652.
   PubMed Web of Science ®Google Scholar
• Wee S, Koob GF. The role of the dynorphin-kappa opioid system in the reinforcing effects of drugs of abuse. Psychopharmacology. 2010;210(2):121–135.
   PubMed Web of Science ®Google Scholar
• Rolland B, Paille F, Gillet C, et al. Pharmacotherapy for alcohol dependence: the 2015 recommendations of the French Alcohol Society, issued in partnership with the European Federation of Addiction Societies. CNS Neurosci Ther. 2016;22(1):25–37.
   PubMed Web of Science ®Google Scholar
• Soyka M. Nalmefene for the treatment of alcohol use disorders: recent data and clinical potential. Expert Opin Pharmacother. 2016;17(4):619–626.
   PubMed Web of Science ®Google Scholar
• Luquiens A, Reynaud M, Aubin HJ. Is controlled drinking an acceptable goal in the treatment of alcohol dependence? A survey of French alcohol specialists. Alcohol Alcohol. 2011;46(5):586–591.
   PubMed Web of Science ®Google Scholar
• Mann K, Bladström A, Torup L, et al. Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene. Biol Psychiatry. 2013;73(8):706–713.
   PubMed Web of Science ®Google Scholar
• Swift RM. Naltrexone and nalmefene: any meaningful difference? Biol Psychiatry. 2013;73(8):700–701.
   PubMed Web of Science ®Google Scholar
• Jonas DE, Amick HR, Feltner C, et al. Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis. JAMA. 2014;311(18):1889–1900.
   PubMed Web of Science ®Google Scholar
• Ingman K, Hagelberg N, Aalto S. et al. Prolonged central μ-opioid receptor occupancy after single and repeated nalmefene dosing. Neuropsychopharmacology. 2005;30(12):2245–2253.
   PubMed Web of Science ®Google Scholar
• Wang DS, Sternbach G, Varon J. Nalmefene: a long-acting opioid antagonist. Clinical applications in emergency medicinet. J Emerg Med. 1998;16(3):471–475.
   PubMedGoogle Scholar
• Gal TJ, DiFazio CA. Prolonged antagonism of opioid action with intravenous nalmefene in man. Anesthesiology. 1986;64(2):175–180.
   PubMed Web of Science ®Google Scholar
• Kaplan JL, Marx JA, Calabro JJ, et al. Double-blind, randomized study of nalmefene and naloxone in emergency department patients with suspected narcotic overdose. Ann Emerg Med. 1999;34(1):42–50.
   PubMed Web of Science ®Google Scholar
• Bristow K, Meek R, Clark N. Acute opioid withdrawal in the emergency department: Inadvertent naltrexone abuse? Emerg Med. 2001;13(3):359–363.
   PubMedGoogle Scholar
• Boyce SH, Armstrong PA, Stevenson J. Effect of inappropriate naltrexone use in a heroin misuser. Emerg Med J. 2003;20(4):381–382.
   PubMed Web of Science ®Google Scholar
• Lubman DI, Koutsogiannis Z, Kronborg I. Emergency management of inadvertent accelerated opiate withdrawal in dependent opiate users. Drug Alcohol Rev. 2003;22(4):433–436.
   PubMed Web of Science ®Google Scholar
• Suzuki J, DeVido J, Kalra I. et al. Initiating buprenorphine treatment for hospitalized patients with opioid dependence: a case series. Am J Addict. 2015;24(1):10–14.
   PubMed Web of Science ®Google Scholar
• Wong A, Macleod D, Robinson J, et al. Oxycodone/naloxone preparation can cause acute withdrawal symptoms when misused parenterally or taken orally. Clin Toxicol. 2015;53(8):815–818.
   Web of Science ®Google Scholar
• Leri F. Co-administration of opioid agonists and antagonists in addiction and pain medicine. Expert Opin Pharmacother. 2008;9(8):1387–1396.
   PubMed Web of Science ®Google Scholar
• Gangahar D. A case of rhabdomyolysis associated with severe opioid withdrawal. Am J Addict. 2015;24(5):400–402.
   PubMed Web of Science ®Google Scholar
• Yeo M, Campbell V, Bonomo Y, et al. Acute opioid withdrawal on accidental injection of naltrexone. J Paediatr Child Health. 2003;39(4):315–317.
   PubMed Web of Science ®Google Scholar
• Singh SM, Sharma B. Unintentional rapid opioid detoxification: case report. Psychiatr Danub. 2009;21(1):65–67.
   PubMed Web of Science ®Google Scholar
• Quigley MA, Boyce SH. Unintentional rapid opioid detoxification. Emerg Med J. 2001;18(6):494–495.
   PubMed Web of Science ®Google Scholar
• Bart G. Maintenance medication for opiate addiction: the foundation of recovery. J Addict Dis. 2012;31(3):207–225.
   PubMed Web of Science ®Google Scholar
• Elefritz JL, Murphy CV, Papadimos TJ, et al. Methadone analgesia in the critically ill. J Crit Care. 2016;34:84–88.
   PubMed Web of Science ®Google Scholar
• Hensel M, Kox WJ. Safety, efficacy, and long-term results of a modified version of rapid opiate detoxification under general anaesthesia: a prospective study in methadone, heroin, codeine and morphine addicts. Acta Anaesthesiol Scand. 2000;44(3):326–333.
   PubMed Web of Science ®Google Scholar
• Matz J, Graff C, Vainio PJ, et al. Effect of nalmefene 20 and 80 mg on the corrected QT interval and T-wave morphology: a randomized, double-blind, parallel-group, placebo- and moxifloxacin-controlled, single-centre study. Clin Drug Investig. 2011;31(11):799–811.
   PubMed Web of Science ®Google Scholar
• Ogbuagu O, Friedland G, Bruce RD. Drug interactions between buprenorphine, methadone and hepatitis C therapeutics. Expert Opin Drug Metab Toxicol. 2016;12(7):721–731.
   PubMed Web of Science ®Google Scholar
• Walsh SL, Preston KL, Stitzer ML, et al. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther. 1994;55(5):569–580.
   PubMed Web of Science ®Google Scholar
• Clark CB, Zyambo CM, Li Y, et al. The impact of non-concordant self-report of substance use in clinical trials research. Addict Behav. 2016;58:74–79.
   PubMed Web of Science ®Google Scholar
• Donny EC, Walsh SL, Bigelow GE, et al. High-dose methadone produces superior opioid blockade and comparable withdrawal suppression to lower doses in opioid-dependent humans. Psychopharmacology (Berl). 2002;161(2):202–212.
   PubMed Web of Science ®Google Scholar
• Ps H, Demirkol A, Lange K, et al. Management of injecting drug users admitted to hospital. Lancet. 2009;374(9697):1284–1293.
   PubMed Web of Science ®Google Scholar
• Shanahan CW, Beers D, Alford DP, et al. A transitional opioid program to engage hospitalized drug users. J Gen Intern Med. 2010;25(8):803–808.
   PubMed Web of Science ®Google Scholar
• Noska A, Mohan A, Wakeman S, et al. Managing opioid use disorder during and after acute hospitalization: a case-based review clarifying methadone regulation for acute care settings. J Addict Behav Ther Rehabil. 2015;4(2):10000138.
   Google Scholar
• Kaplan JL, Marx JA. Effectiveness and safety of intravenous nalmefene for emergency department patients with suspected narcotic overdose: a pilot study. Ann Emerg Med. 1993;22(2):187–190.
   PubMed Web of Science ®Google Scholar
• Suzuki J. Medication-assisted treatment for hospitalized patients with intravenous-drug-use related infective endocarditis. Am J Addict. 2016;25(3):191–194.
   PubMed Web of Science ®Google Scholar
• Liebschutz JM, Crooks D, Herman D, et al. Buprenorphine treatment for hospitalized, opioid-dependent patients: a randomized clinical trial. JAMA Intern Med. 2014;174(8):1369–1376.
   PubMed Web of Science ®Google Scholar
• Nielsen S, Dietze P, Lee N, et al. Concurrent buprenorphine and benzodiazepines use and self-reported opioid toxicity in opioid substitution treatment. Addiction. 2007;102(4):616–622.
   PubMed Web of Science ®Google Scholar
• Yarborough BJ, Stumbo SP, McCarty D, et al. Methadone, buprenorphine and preferences for opioid agonist treatment: a qualitative analysis. Drug Alcohol Depend. 2016;160:112–118.
   PubMed Web of Science ®Google Scholar
• Sigmon SC. Interim treatment: bridging delays to opioid treatment access. Prev Med. 2015;80:32–36.
   PubMed Web of Science ®Google Scholar
• Soyka M. Alcohol use disorders in opioid maintenance therapy: prevalence, clinical correlates and treatment. Eur Addict Res. 2015;21(2):78–87.
   PubMed Web of Science ®Google Scholar
• Srivastava A, Kahan M, Ross S. The effect of methadone maintenance treatment on alcohol consumption: a systematic review. J Subst Abuse Treat. 2008;34(2):215–223.
   PubMed Web of Science ®Google Scholar
• Verelst S, Moonen PJ, Desruelles D, et al. Emergency department visits due to alcohol intoxication: characteristics of patients and impact on the emergency room. Alcohol Alcohol. 2012;47(4):433–438.
   PubMed Web of Science ®Google Scholar
• Blow FC, Walton MA, Murray R, et al. Intervention attendance among emergency department patients with alcohol- and drug-use disorders. J Stud Alcohol Drugs. 2010;71(5):713–719.
   PubMed Web of Science ®Google Scholar
• Breslin KT, Malone S. Maintaining the viability and safety of the methadone maintenance treatment program. J Psychoactive Drugs. 2006;38(2):157–160.
   PubMed Web of Science ®Google Scholar
• Vl K, Ms K, Kb S, et al. A 12-month controlled trial of methadone medical maintenance integrated into an adaptive treatment model. J Subst Abuse Treat. 2006;31(4):385–393.
   PubMed Web of Science ®Google Scholar
• Strike C, Millson M, Hopkins S, et al. What is low threshold methadone maintenance treatment? Int J Drug Policy. 2013;24(6):e51–56.
   PubMedGoogle Scholar
• Nolan S, Hayashi K, M-J M, et al. The impact of low-threshold methadone maintenance treatment on mortality in a Canadian setting. Drug Alcohol Depend. 2015;156:57–61.
   PubMed Web of Science ®Google Scholar
• D’Onofrio G, O’Connor PG, Pantalon MV. et al. Emergency department–initiated buprenorphine/naloxone treatment for opioid dependence. JAMA. 2015;313(16):1636–1644.
   PubMed Web of Science ®Google Scholar
• Gowing L, Farrell M, Ali R, et al. Alpha2-adrenergic agonists for the management of opioid withdrawal. Cochrane Database Syst Rev. 2016;5:CD002024. DOI:10.1002/14651858
   PubMed Web of Science ®Google Scholar
• Amato L, Minozzi S, Davoli M, et al. Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification. Cochrane Database Syst Rev. 2011;9:CD005031.
   Google Scholar
• Touquet R, Brown A. PAT (2009) – revisions to the Paddington Alcohol Test for early identification of alcohol misuse and brief advice to reduce emergency department re-attendance. Alcohol Alcohol. 2009;44(3):284–286.
   PubMed Web of Science ®Google Scholar
• Huntley JS, Patton R, Touquet R. Attitudes towards alcohol of emergency department doctors trained in the detection of alcohol misuse. Ann R Coll Surg Engl. 2004;86(5):329–333.
   PubMed Web of Science ®Google Scholar
• Wiechers IR, Freudenreich O. The role of consultation-liaison psychiatrists in improving health care of patients with schizophrenia. Psychosomatics. 2013;54(1):22–27.
   PubMed Web of Science ®Google Scholar
• Jones HE, Deppen K, Hudak ML, et al. Clinical care for opioid-using pregnant and postpartum women: the role of obstetric providers. Am J Obstet Gynecol. 2014;210(4):302–310.
   PubMed Web of Science ®Google Scholar
• Franchitto N. How may addiction specialists assist emergency physicians in increasing the accuracy of ICD-10 codes in substance use disorder? Am J Emerg Med. 2015;33(12):1835–1836.
   PubMed Web of Science ®Google Scholar
• Kunz K, Wiegand T. Addiction medicine: current status of certification, maintenance of certification, training, and practice. J Med Toxicol. 2015;12(1):76–78.
   Google Scholar